DIRECT AND INDIRECT COSTS ASSOCIATED WITH UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) FOR PATIENTS AND THEIR CAREGIVERS

被引：0
|
作者：
Hall, J. [1 ]
Khela, K. [1 ]
Bertwistle, D. [2 ]
Xiao, H. [3 ]
机构：
[1] Adelphi Real World, Bollington, England
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Lawrence Township, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN340
引用
收藏
页码：S482 / S483
页数：2
相关论文
共 50 条
  • [31] Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
    Peng, Zhi
    Li, Zhongwu
    Gao, Jing
    Lu, Ming
    Gong, Jifang
    Tang, En-Tzu
    Oliner, Kelly S.
    Hei, Yong-Jiang
    Zhou, Hui
    Shen, Lin
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (11) : 2634 - 2641
  • [32] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
    Sugarman, Ryan
    Botteman, Marc
    Rusibamayila, Nifasha
    Nguyen, Hiep
    Lin, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [33] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
    Moehler, Markus H.
    Shitara, Kohei
    Garrido, Marcelo
    Salman, Pamela
    Shen, Lin
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Schenker, Michael
    Yanez, Patricio Eduardo
    Tehfe, Mustapha
    Li, Mingshun
    Cullen, Dana
    Memaj, Arteid
    Lei, Ming
    Xiao, Hong
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Elimova, Elena
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)
    Moehler, M.
    Wyrwicz, L.
    Chen, C.
    Davenport, E.
    Wang, J.
    Nathani, R.
    Kondo, K.
    Elimova, E.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S185 - S185
  • [36] Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
    Shitara, Kohei
    Janjigian, Yelena Y.
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Silva, Arinilda
    Bragagnoli, Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Soleymani, Samira
    Lei, Ming
    Kondo, Kaoru
    Li, Mingshun
    Ajani, Jaffer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Moehler, M.
    Janjigian, Y. Y.
    Shitara, K.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Bruges, R.
    Cleary, J. M.
    Karamouzis, M.
    Soleymani, S.
    Lei, M.
    Amaya, Chanaga C.
    Ajani, J. A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
  • [38] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 306 - 306
  • [39] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Cleary, James M.
    Karamouzis, Michalis
    Soleymani, Samira
    Lei, Ming
    Amaya-Chanaga, Carlos
    Ajani, Jaffer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
    Meng, Xiangrui
    Shan, Zhengzheng
    Guan, Lulu
    Dao, Xin
    Fan, Qingxia
    Wang, Feng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 335 - 335
12345